22nd Century GroupXXII
About: 22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
Employees: 64
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
412% more capital invested
Capital invested by funds: $143K [Q2] → $732K (+$589K) [Q3]
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
13.49% more ownership
Funds ownership: 2.32% [Q2] → 15.81% (+13.49%) [Q3]
6% more funds holding
Funds holding: 33 [Q2] → 35 (+2) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for XXII.
Financial journalist opinion
Based on 3 articles about XXII published over the past 30 days